CREDIT AGREEMENT Dated as of December 27, 2023 among CALLIDITAS THERAPEUTICS AB, as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER, as the Guarantors, ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent and THE LENDERS FROM TIME...Credit Agreement • April 24th, 2024 • Calliditas Therapeutics AB • Pharmaceutical preparations • New York
This CREDIT AGREEMENT is entered into as of December 27, 2023 among CALLIDITAS THERAPEUTICS AB, a Swedish public limited liability company with Swedish registration number 556659-9766 (the “Borrower”), the Guarantors (defined herein), the Lenders (defined herein) and ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER...Master Manufacturing Services Agreement • April 24th, 2024 • Calliditas Therapeutics AB • Pharmaceutical preparations
With effect from the date stated at the start of this Agreement (the “Effective Date”), the parties have agreed to the following terms:
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER...Product Agreement • April 24th, 2024 • Calliditas Therapeutics AB • Pharmaceutical preparations
This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated December 30, 2020 between Patheon Pharmaceuticals Inc. and Calliditas Therapeutics AB (the “Master Agreement”), and is entered into on December 30, 2020 (the “Effective Date”) between Patheon Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, with its principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237 (“Patheon”) and Calliditas Therapeutics AB, a company existing under the laws of Sweden, with its principal place of business at Kungsbron 1, C8, SE-111 22 Stockholm (“Client”). For the purpose of this Product Agreement, references in the Master Agreement to “Patheon” and “Client” mean the entities defined respectively as Patheon and Client in this Product Agreement.
